RTTNews | Apr 5, 2021 09:55AM EDT

09:55 Monday, April 5, 2021 (RTTNews.com) - Shares of Supernus Pharmaceuticals, Inc. (SUPN) are up more than 7% Monday morning at $28.72.

On Aprii 2, Supernus had announced that Qelbree, the company's drug candidate, has been approved by the FDA for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age.

SUPN has been trading in the range of $16.54- $31.99 in the past 52 weeks.

Read the original article on RTTNews ( https://www.rttnews.com/3182466/stock-alert-supernus-pharmaceuticals-up-7-after-fda-approves-its-qelbree-to-treat-adhd.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved